Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic

COVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney...

Full description

Bibliographic Details
Main Authors: Juan Li, Shuang-Xi Li, Li-Fang Zhao, De-Liang Kong, Zhi-Yong Guo
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2020-06-01
Series:Chronic Diseases and Translational Medicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2095882X20300402
id doaj-b422c05ebc4e4a76b952dabeaca85184
record_format Article
spelling doaj-b422c05ebc4e4a76b952dabeaca851842021-04-02T12:30:33ZengKeAi Communications Co., Ltd.Chronic Diseases and Translational Medicine2095-882X2020-06-0162119123Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemicJuan Li0Shuang-Xi Li1Li-Fang Zhao2De-Liang Kong3Zhi-Yong Guo4Department of Nephrology, Changhai Hospital, Shanghai 200433, ChinaDepartment of Nephrology, Changhai Hospital, Shanghai 200433, ChinaDepartment of Nephrology, Changhai Hospital, Shanghai 200433, ChinaDepartment of Nephrology, Changhai Hospital, Shanghai 200433, ChinaCorresponding author. Department of Nephrology, Changhai Hospital, 168 Changhai Rd, Shanghai 200433, China.; Department of Nephrology, Changhai Hospital, Shanghai 200433, ChinaCOVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney and cause acute tubular necrosis, leading to proteinuria, hematuria and elevated serum creatinine. Since the SARS-CoV-2 enters the cells by binding to the angiotensin-converting enzyme 2 receptor, some doctors question its ability to increase the risk and severity of developing COVID-19. Neither clinical data nor basic scientific evidence supports this assumption. Therefore, patients who take angiotensin-converting enzyme inhibitor or angiotensin receptor blocker are not advised to change their therapy. Patients with CKD are generally the elderly population suffering from multiple comorbidities. Moreover, some patients with CKD might need to take glucocorticoids and immunosuppressants. Dialysis patients are recurrently exposed to a possible contaminated environment because their routine treatment usually requires three dialysis sessions per week. Considering all the above reasons, patients with CKD are more vulnerable to COVID-19 than the general population. The development of COVID-19 may worsen the impaired kidney function and further lead to rapid deterioration of kidney function and even death. Strict comprehensive protocols should be followed to prevent the spread of COVID-19 among patients with CKD. In this review, we provide some practical management recommendations for health care providers, patients with CKD, dialysis patients and dialysis facilities.http://www.sciencedirect.com/science/article/pii/S2095882X20300402Coronavirus disease 2019COVID-19Novel coronavirusChronic kidney diseaseManagement
collection DOAJ
language English
format Article
sources DOAJ
author Juan Li
Shuang-Xi Li
Li-Fang Zhao
De-Liang Kong
Zhi-Yong Guo
spellingShingle Juan Li
Shuang-Xi Li
Li-Fang Zhao
De-Liang Kong
Zhi-Yong Guo
Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
Chronic Diseases and Translational Medicine
Coronavirus disease 2019
COVID-19
Novel coronavirus
Chronic kidney disease
Management
author_facet Juan Li
Shuang-Xi Li
Li-Fang Zhao
De-Liang Kong
Zhi-Yong Guo
author_sort Juan Li
title Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_short Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_full Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_fullStr Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_full_unstemmed Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic
title_sort management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (covid-19) epidemic
publisher KeAi Communications Co., Ltd.
series Chronic Diseases and Translational Medicine
issn 2095-882X
publishDate 2020-06-01
description COVID-19 has become a pandemic and it has already spread to at least 171 countries/regions. Chronic kidney disease (CKD) is a global public health problem with a total of approximately 850 million patients with CKD worldwide and 119.5 million in China. Severe COVID-19 infection may damage the kidney and cause acute tubular necrosis, leading to proteinuria, hematuria and elevated serum creatinine. Since the SARS-CoV-2 enters the cells by binding to the angiotensin-converting enzyme 2 receptor, some doctors question its ability to increase the risk and severity of developing COVID-19. Neither clinical data nor basic scientific evidence supports this assumption. Therefore, patients who take angiotensin-converting enzyme inhibitor or angiotensin receptor blocker are not advised to change their therapy. Patients with CKD are generally the elderly population suffering from multiple comorbidities. Moreover, some patients with CKD might need to take glucocorticoids and immunosuppressants. Dialysis patients are recurrently exposed to a possible contaminated environment because their routine treatment usually requires three dialysis sessions per week. Considering all the above reasons, patients with CKD are more vulnerable to COVID-19 than the general population. The development of COVID-19 may worsen the impaired kidney function and further lead to rapid deterioration of kidney function and even death. Strict comprehensive protocols should be followed to prevent the spread of COVID-19 among patients with CKD. In this review, we provide some practical management recommendations for health care providers, patients with CKD, dialysis patients and dialysis facilities.
topic Coronavirus disease 2019
COVID-19
Novel coronavirus
Chronic kidney disease
Management
url http://www.sciencedirect.com/science/article/pii/S2095882X20300402
work_keys_str_mv AT juanli managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic
AT shuangxili managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic
AT lifangzhao managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic
AT deliangkong managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic
AT zhiyongguo managementrecommendationsforpatientswithchronickidneydiseaseduringthenovelcoronavirusdisease2019covid19epidemic
_version_ 1721568767587123200